{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T02:48:37Z","timestamp":1780541317769,"version":"3.54.1"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jurology.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.juro.2017.08.080","type":"journal-article","created":{"date-parts":[[2017,8,19]],"date-time":"2017-08-19T03:30:22Z","timestamp":1503113422000},"page":"147-154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial"],"prefix":"10.1097","volume":"199","author":[{"given":"D. Robert","family":"Siemens","sequence":"first","affiliation":[{"name":"Centre for Applied Urological Research, Queen\u2019s University, Kingston, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Klotz","sequence":"additional","affiliation":[{"name":"Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Heidenreich","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"Guy\u2019s, King\u2019s and St Thomas\u2019 Hospitals, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnauld","family":"Villers","sequence":"additional","affiliation":[{"name":"Department of Urology, Lille University, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Baron","sequence":"additional","affiliation":[{"name":"Astellas Pharma, Inc., Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"van Os","sequence":"additional","affiliation":[{"name":"Astellas Pharma, Inc., Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahla","family":"Hasabou","sequence":"additional","affiliation":[{"name":"Astellas Pharma, Inc., Northbrook, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fong","family":"Wang","sequence":"additional","affiliation":[{"name":"Medivation, Inc., which was acquired by Pfizer, Inc. in September 2016, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Lin","sequence":"additional","affiliation":[{"name":"Medivation, Inc., which was acquired by Pfizer, Inc. in September 2016, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal D.","family":"Shore","sequence":"additional","affiliation":[{"name":"Carolina Urologic Research Center, Myrtle Beach, South Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2017.08.080_bib1","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/cam4.576","article-title":"Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data","volume":"5","author":"Flaig","year":"2016","journal-title":"Cancer Med"},{"key":"10.1016\/j.juro.2017.08.080_bib2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jgo.2013.12.001","article-title":"Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial","volume":"5","author":"Horgan","year":"2014","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.juro.2017.08.080_bib3","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.prnil.2015.03.003","article-title":"Docetaxel in very elderly men with metastatic castration-resistant prostate cancer","volume":"3","author":"Wong","year":"2015","journal-title":"Prostate Int"},{"key":"10.1016\/j.juro.2017.08.080_bib4","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1200\/JCO.2013.54.8404","article-title":"Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline","volume":"32","author":"Basch","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2017.08.080_bib5","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2017.08.080_bib6","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2017.08.080_bib7","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1470-2045(15)00518-5","article-title":"Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study","volume":"17","author":"Shore","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.juro.2017.08.080_bib8","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.eururo.2016.07.027","article-title":"Impact of enzalutamide compared with bicalutamide on quality of life in men with metastatic castration-resistant prostate cancer: additional analyses from the TERRAIN Randomised Clinical Trial","volume":"71","author":"Heidenreich","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2017.08.080_bib9","unstructured":"Food and Drug Administration: Guidance for Industry E7 Studies in Support of Special Populations: Geriatrics Questions and Answers. Available at http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM189544.pdf. Accessed April 27, 2017."},{"key":"10.1016\/j.juro.2017.08.080_bib10","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/annonc\/mdt571","article-title":"Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial","volume":"25","author":"Sternberg","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.juro.2017.08.080_bib11","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/annonc\/mdv542","article-title":"Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL","volume":"27","author":"Graff","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.juro.2017.08.080_bib12","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.eururo.2016.06.033","article-title":"Subsequent chemotherapy and treatment patterns after abiraterone acetate in patients with metastatic castration-resistant prostate cancer: Post hoc analysis of COU-AA-302","volume":"71","author":"de Bono","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2017.08.080_bib13","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.3109\/0284186X.2013.770164","article-title":"Population-based study on use of chemotherapy in men with castration resistant prostate cancer","volume":"52","author":"Lissbrant","year":"2013","journal-title":"Acta Oncol"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534717773776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534717773776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2017.08.080","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T05:09:38Z","timestamp":1651208978000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2017.08.080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1016\/j.juro.2017.08.080"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2017.08.080","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial","name":"articletitle","label":"Article Title"},{"value":"The Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.juro.2017.08.080","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by AMERICAN UROLOGICAL ASSOCIATION EDUCATION AND RESEARCH, INC.","name":"copyright","label":"Copyright"}]}}